Tirzepatide
glucagon-like-peptide-1 (GLP-1) receptor agonist
What is Tirzepatide?
Tirzepatide (Mounjaro) is a dual GIP/GLP-1 receptor agonist that has demonstrated remarkable efficacy in weight management and the treatment of type 2 diabetes. It works by:
-
Reducing appetite
-
Slowing gastric emptying
-
Promoting a feeling of fullness
​
These mechanisms help lower caloric intake and support sustainable weight loss.
Clinical studies have shown that tirzepatide can achieve an average weight loss of up to 20-22% of body weight when combined with a healthy diet and active lifestyle. This makes it a powerful option for individuals seeking significant weight reduction.
​​
Its unique dual action on both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 pathways sets tirzepatide apart, offering superior results in weight loss and metabolic health compared to single-pathway treatments.
Weight Loss: Up to 20 - 22%
Is Tirzepatide right for you?
Discover if Tirzepatide is the right choice for your weight loss journey. Book a consultation today and let our expert team guide you toward achieving your goals.